Last Update: Jul 15, 2026
Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
ClinicalTrials.gov Identifier:
NCT07543731
Novartis Reference Number:CKJX839A12404
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.

Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial
Recruiting
5995
Apr 02, 2026
Oct 30, 2026
All
18 Years - 99 Years (Adult, Older Adult)

Eligibility Criteria

Inclusion criteria:

* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
* Age ≥18 years at index date.
* With at least 12 months data availability prior to index date.

Exclusion criteria:

• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.

Novartis

Recruiting

Basel,Ch-4056,Switzerland

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111